id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S18401 R77649 |
Kernizan (Controls exposed to LTG), 2024 | C-section delivery | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.20 [0.32;4.51] C excluded (control group) |
16/46 4/13 | 20 | 46 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S18348 R77612 |
Kernizan (Controls unexposed, sick), 2024 | C-section delivery | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No | 1.04 [0.52;2.10] C | 16/46 47/139 | 63 | 46 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S18338 R77579 |
Kulkarni - Quetiapine, 2024 | Cesarean delivery | at least 1st trimester excluded | prospective cohort | unexposed, sick | Adjustment: No |
1.87 [0.67;5.21] C excluded (exposition period) |
24/44 9/23 | 33 | 44 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3851 R8194 |
Ellfolk (Control exposed to FGA), 2019 | Cesarean section | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: Yes |
1.25 [1.03;1.51] excluded (control group) |
1,057/4,225 336/1,576 | 1,393 | 4,225 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3818 R8129 |
Ellfolk (Control unexposed), 2019 | Cesarean section | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 1.35 [1.18;1.53] | 1,057/4,225 3,251/21,125 | 4,308 | 4,225 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3905 R8275 |
Schaffer (Controls unexposed, NOS), 2019 | Caesarean section | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) excluded | Adjustment: No |
1.36 [1.21;1.53] C excluded (control group) |
415/1,322 34,004/135,200 | 34,419 | 1,322 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3907 R8284 |
Schaffer (Controls unexposed, sick), 2019 | Caesarean section | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: No | 1.24 [1.05;1.46] C | 415/1,322 383/1,419 | 798 | 1,322 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2336 R3009 |
Petersen (Control discontinued treatment before pregnancy), 2016 | Caesarean section | 1st trimester excluded | retrospective cohort (claims database) | unexposed, sick | Adjustment: No |
1.15 [0.78;1.68] C excluded (exposition period) |
69/280 67/302 | 136 | 280 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3847 R8171 |
Petersen (Control exposed to FGA), 2016 | Caesarean section | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
0.90 [0.57;1.40] C excluded (control group) |
69/280 42/157 | 111 | 280 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2398 R3010 |
Petersen (Control unexposed, disease free), 2016 | Caesarean section | 1st trimester | retrospective cohort (claims database) | unexposed, disease free excluded | Adjustment: No |
1.45 [1.11;1.91] C excluded (control group) |
69/280 58,532/318,434 | 58,601 | 280 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2294 R8214 |
Vigod, 2015 | Caesarean section | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Matched | 0.97 [0.82;1.13] | 317/1,021 325/1,021 | 642 | 1,021 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2332 R8153 |
Peng, 2013 | Caesarean | throughout pregnancy | prospective cohort | unexposed, disease free | Adjustment: No Matched | 1.70 [0.90;3.24] C | 40/76 30/76 | 70 | 76 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2286 R8151 |
Sadowski, 2013 | C-section (repeat, emergency and schedules) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free | Adjustment: No Matched | 1.48 [0.82;2.66] C | 35/113 27/116 | 62 | 113 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3842 R8161 |
Hironaka (Control exposed to BZD), 2011 | Emergency cesarean section | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.80 [0.06;54.33] C excluded (control group) |
1/9 0/5 | 1 | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2334 R3595 |
Hironaka (Control unexposed, disease free), 2011 | Emergency cesarean section | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, disease free excluded | Adjustment: No |
2.19 [0.26;18.68] C excluded (control group) |
1/9 15/278 | 16 | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S14447 R57311 |
Hironaka (Control unexposed, sick), 2011 | Emergency cesarean section | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No | 1.00 [0.03;33.32] C | 1/9 0/3 | 1 | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 7 studies | 1.21 [1.04;1.41] | 5,944 | 6,812 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Controls unexposed, sick; 2: Control unexposed; 3: Controls unexposed, sick; 4: Control unexposed, sick;
Asymetry test p-value = 0.8555 (by Egger's regression)
slope=0.1731 (0.1071); intercept=0.1814 (0.9463); t=0.1917; p=0.8555
excluded 3842, 2334, 3847, 2398, 3851, 3905, 18401